Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

NEURODEGENERATIVE DISEASE

New antisense oligonucleotide therapies reach first base in ALS

Nature Medicine volume 28, pages 25–27 (2022)Cite this article

Subjects

Two studies highlight the evolution of antisense oligonucleotide therapy for amyotrophic lateral sclerosis, offering hope for an effective treatment.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: ASO therapies in ALS.

References

  1. Deng, H. X. et al. Science 261, 1047–1051 (1993).

    Article  CAS  Google Scholar 

  2. Rosen, D. R. et al. Nature 362, 59–62 (1993).

    Article  CAS  Google Scholar 

  3. Finkel, R. S. et al. N. Engl. J. Med. 377, 1723–1732 (2017).

    Article  CAS  Google Scholar 

  4. Mercuri, E. et al. N. Engl. J. Med. 378, 625–635 (2018).

    Article  CAS  Google Scholar 

  5. Tran, H. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01557-6 (2021).

    Article  PubMed  Google Scholar 

  6. Korobeynikov, V. A. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01615-z (2021).

    Article  Google Scholar 

  7. DeJesus-Hernandez, M. et al. Neuron 72, 245–256 (2011).

    Article  CAS  Google Scholar 

  8. Renton, A. E. et al. Neuron 72, 257–268 (2011).

    Article  CAS  Google Scholar 

  9. Kingwell, K. Nat. Rev. Drug Discov. 20, 412–413 (2021).

    Article  CAS  Google Scholar 

  10. Biogen announces topline results from the tofersen phase 3 study and its open-label extension in SOD1-ALS. Biogen (17 October 2021).

  11. Miller, T. et al. N. Engl. J. Med. 383, 109–119 (2020).

    Article  CAS  Google Scholar 

  12. Gennemark, P. et al. Sci. Transl. Med. 13, eabe9117 (2021).

    Article  CAS  Google Scholar 

  13. Nagata, T. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-021-00972-x (2021).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by the Intramural Research Programs of the National Center for Advancing Translational Sciences and the National Institute on Aging, National Institutes of Health (Z01-AG000949-02).

Author information

Authors and Affiliations

  1. Therapeutic Development Branch, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA

    Elia R. Lopez, William F. Borschel & Bryan J. Traynor

  2. Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA

    Bryan J. Traynor

Authors
  1. Elia R. Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William F. Borschel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bryan J. Traynor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bryan J. Traynor.

Ethics declarations

Competing interests

B.J.T. holds the US, Canadian and European patents on the clinical testing and therapeutic intervention for the hexanucleotide repeat expansion in C9orf72.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lopez, E.R., Borschel, W.F. & Traynor, B.J. New antisense oligonucleotide therapies reach first base in ALS. Nat Med 28, 25–27 (2022). https://doi.org/10.1038/s41591-021-01629-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01629-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research